News
VTRS
12.52
+3.22%
0.39
Weekly Report: what happened at VTRS last week (1216-1220)?
Weekly Report · 8h ago
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Benzinga · 22h ago
Materials, software stocks are best poised for H1 outperformance: Goldman Sachs
Seeking Alpha · 1d ago
UBS says ‘underweight the names with high China exposure’
Seeking Alpha · 3d ago
Viatris announces publication of CARE study results
TipRanks · 5d ago
Viatris Announces Publication Of Phase 2b CARE Study Results For Cenerimod, Demonstrating Efficacy In Moderate-To-Severe Lupus
Benzinga · 5d ago
Analysts Offer Insights on Healthcare Companies: Viatris (VTRS) and Airsculpt Technologies, Inc. (AIRS)
TipRanks · 6d ago
Weekly Report: what happened at VTRS last week (1209-1213)?
Weekly Report · 12/16 09:28
Weekly Report: what happened at VTRS last week (1202-1206)?
Weekly Report · 12/09 09:27
Viatris Elects Directors and Amends Stock Plan at Meeting
TipRanks · 12/06 22:48
Piper Sandler Reiterates Neutral on Viatris, Raises Price Target to $14
Benzinga · 12/06 14:20
Viatris price target raised to $14 from $13 at Piper Sandler
TipRanks · 12/06 13:02
Tracking David Einhorn's Greenlight Capital Portfolio - Q3 2024 Update
Seeking Alpha · 12/06 02:08
Weekly Report: what happened at VTRS last week (1125-1129)?
Weekly Report · 12/02 09:27
Wolfe’s most shorted ‘Hit List’ – FSLR, BE, WBA, SJM
Seeking Alpha · 11/26 19:01
Weekly Report: what happened at VTRS last week (1118-1122)?
Weekly Report · 11/25 09:25
Viatris Breaches UK Competition Watchdog's Order; Fined £1.5 Mln
NASDAQ · 11/22 13:04
Viatris fined £1.5M for failure to comply with CMA order
Seeking Alpha · 11/22 11:26
BUZZ-Viatris falls after $1.9 mln fine by UK watchdog
Reuters · 11/22 11:24
UK'S CMA: CMA FOUND THAT VIATRIS FAILED TO COMPLY WITH COMPULSORY RESTRICTIONS IMPOSED DURING CMA’S REVIEW OF ITS DEAL WITH THERAMEX
Reuters · 11/22 09:32
More
Webull provides a variety of real-time VTRS stock news. You can receive the latest news about Viatris Inc Ord Shs through multiple platforms. This information may help you make smarter investment decisions.
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s ARV franchise. The Company’s portfolio comprises approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands and generics, including complex products. The Company operates manufacturing sites across worldwide that produce oral solid doses, injectables and complex dosage forms.